Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
December 16, 2025

Enhertu / trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies as of May 2021

MARA Rating Company December 16, 2025

Enhertu / trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments as of February 2023

MARA Rating Company December 16, 2025

Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy as of July 2024

MARA Rating Company December 16, 2025

Trifluridine-tipiracil for treating metastatic gastric cancer or gastrooesophageal junction adenocarcinoma after 2 or more treatments as of December 2022

MARA Rating Company December 16, 2025

Trifluridine-tipiracil plus bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments as of September 2024

MARA Rating Company December 16, 2025

Tukysa / tucatinib for treating HER2-positive locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies as of April 2022

MARA Rating Company December 16, 2025

Ublituximab for treating relapsing forms of multiple sclerosis as of December 2024

MARA Rating Company December 16, 2025

Teduglutide for treating short bowel syndrome as of June 2022

MARA Rating Company December 16, 2025

Tenecteplase for treating acute ischaemic stroke as of July 2024

MARA Rating Company December 16, 2025

Tepmetko / tepotinib for treating advanced non-small-cell lung cancer with METex14 skipping alterations as of May 2022

MARA Rating Company December 16, 2025